Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $54.8 million.

  • Stoke Therapeutics' Shares Outstanding (Weighted Average) rose 4.08% to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $53.0 million for FY2024, which is 18.62% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Shares Outstanding (Weighted Average) of $54.8 million as of Q3 2025, which was up 0.37% from $54.6 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Shares Outstanding (Weighted Average) peaked at $54.8 million during Q3 2025, and registered a low of $37.4 million during Q1 2022.
  • For the 3-year period, Stoke Therapeutics' Shares Outstanding (Weighted Average) averaged around $49.5 million, with its median value being $52.1 million (2024).
  • Data for Stoke Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 18.96% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Shares Outstanding (Weighted Average) stood at $39.4 million in 2022, then increased by 13.25% to $44.7 million in 2023, then climbed by 18.62% to $53.0 million in 2024, then rose by 4.08% to $54.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $54.8 million in Q3 2025, compared to $54.6 million in Q2 2025 and $54.1 million in Q1 2025.